William John Scheessele - 21 Jan 2025 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Reporting relationship: Chief Commercial Officer
Issuer ticker: HUMA
Reported as of: 21 Jan 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jan 2025, 16:34:58 UTC
Prior SEC filing: 12 Dec 2023
Next SEC filing: 15 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ William John Scheessele by Dale A. Sander as Attorney-in-Fact

Key filing fact

William John Scheessele filed Form 4 for Humacyte, Inc. (HUMA) on 23 Jan 2025.

Key facts

This page summarizes William John Scheessele's Form 4 filing for Humacyte, Inc. (HUMA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Jan 2025, 16:34.

Change

Previous filing in this sequence was filed on 12 Dec 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HUMA transaction Derivative

Stock Options (right to buy)

Award

Transaction value: $0
Shares: +283,101
Change %
Price: $0.000000
Shares after: 283,101
Date: 21 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 283,101
Exercise price: $4.56
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through January 21, 2029.